These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11873057)

  • 21. Spontaneous occurrence of the disposition to malignant hyperthermia.
    Rueffert H; Olthoff D; Deutrich C
    Anesthesiology; 2004 Mar; 100(3):731-3. PubMed ID: 15108991
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical variability in the onset of life-threatening malignant hyperthermia: two case reports.
    Heytens LG; Vercauteren M
    Eur J Anaesthesiol; 2013 Apr; 30(4):189-90. PubMed ID: 23325059
    [No Abstract]   [Full Text] [Related]  

  • 23. Malignant hyperthermia as a cause for postoperative rhabdomyolysis.
    Wappler F; Fiege M
    Anesthesiology; 2000 Apr; 92(4):1206-7. PubMed ID: 10754651
    [No Abstract]   [Full Text] [Related]  

  • 24. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant hyperthermia: update on susceptibility testing.
    Litman RS; Rosenberg H
    JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Malignant hyperthermia].
    Takagi A
    Ryoikibetsu Shokogun Shirizu; 2001; (36):423-9. PubMed ID: 11596428
    [No Abstract]   [Full Text] [Related]  

  • 27. In hot pursuit.
    Hogan K
    Anesthesiology; 2006 Dec; 105(6):1077-8. PubMed ID: 17122568
    [No Abstract]   [Full Text] [Related]  

  • 28. A "crush" course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician.
    Cote DR; Fuentes E; Elsayes AH; Ross JJ; Quraishi SA
    J Anesth; 2020 Aug; 34(4):585-598. PubMed ID: 32424487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Core myopathies and malignant hyperthermia susceptibility: a review.
    Brislin RP; Theroux MC
    Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Exciting Couple.
    Etlinger JD
    J Pediatr Ophthalmol Strabismus; 2018 May; 55(3):149-150. PubMed ID: 29796677
    [No Abstract]   [Full Text] [Related]  

  • 32. Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
    Muniz VP; Silva HC; Tsanaclis AM; Vainzof M
    J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient.
    Newmark JL; Voelkel M; Brandom BW; Wu J
    Anesthesiology; 2007 Aug; 107(2):350-3. PubMed ID: 17667581
    [No Abstract]   [Full Text] [Related]  

  • 35. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al.
    Vladutiu G
    Arthritis Rheum; 2007 Feb; 57(1):186-7; author reply 187-8. PubMed ID: 17266123
    [No Abstract]   [Full Text] [Related]  

  • 36. Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome.
    Witting N; Laforêt P; Voermans NC; Roux-Buisson N; Bompaire F; Rendu J; Duno M; Feillet F; Kamsteeg EJ; Poulsen NS; Dahlqvist JR; Romero NB; Fauré J; Vissing J; Behin A
    Acta Neurol Scand; 2018 May; 137(5):452-461. PubMed ID: 29635721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population.
    Kraeva N; Riazi S; Loke J; Frodis W; Crossan ML; Nolan K; Kraev A; Maclennan DH
    Can J Anaesth; 2011 Jun; 58(6):504-13. PubMed ID: 21455645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant Hyperthermia: From the OR to the Sidelines.
    Nelson TE
    Curr Sports Med Rep; 2018 Aug; 17(8):254-255. PubMed ID: 30095544
    [No Abstract]   [Full Text] [Related]  

  • 39. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
    Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
    J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postanaesthetic myoglobinuric renal failure: an isolated expression of malignant hyperthermia.
    Acquarone N; Garibotto G; Tegazzin V; Sofia A; Gurreri G
    Nephrol Dial Transplant; 1994; 9(5):567-8. PubMed ID: 8090342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.